Skip to content

Probiotics Against Low Grade Inflammation and Increased Intestinal Permeability in the Elderly

Probiotics Against Low Grade Inflammation and Increased Intestinal Permeability in the Elderly.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02342496
Enrollment
66
Registered
2015-01-21
Start date
2015-01-31
Completion date
2015-12-04
Last updated
2018-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Increased Intestinal Permeability, Low-grade Inflammation

Brief summary

The purpose of this study is to evaluate the ability of a blend of berries and probiotics in reducing low-grade inflammation and intestinal permeability in the elderly. The intervention period is one month. Blood and fecal samples will be collected for analysis at baseline and at the end of the intervention with the aim to analyse possible changes in different parameters at the two timepoints. The participants will also be asked to keep a study diary throughout the study period for the documentation of their intestinal health and as a means for checking compliance.

Interventions

DIETARY_SUPPLEMENTPlacebo

Powder

DIETARY_SUPPLEMENTActive, only probiotics

Powder

DIETARY_SUPPLEMENTActive, blend of berries and probiotics

Powder

Sponsors

Lund University
CollaboratorOTHER
Probi AB
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
75 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

* Age \>75 years * CRP 2-10 mg/L * Ability to fill in a study diary by him/herself

Exclusion criteria

* Intake of antibiotic treatment in the last 4 weeks before inclusion into the study. * Currently on corticosteroid treatment * Presence of chronic inflammatory disease

Design outcomes

Primary

MeasureTime frame
Reduced intestinal permebility measured as decline in the levels of zonulin in blood samplesAll blood markers analysed in the study will be measured at start, before the onset of intervention and 4 weeks later at the end of intervention.

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 7, 2026